2.50
Hdl Handle:
http://hdl.handle.net/10755/165121
Category:
Abstract
Type:
Presentation
Title:
CASE STUDY: LEUCOVORIN HYPERSENSITIVITY, MORE COMMON THAN YOU MIGHT THINK.
Author(s):
Schumann, Mary
Author Details:
Mary Schumann, RN MA AOCN, Clinical Nurse Specialist, Memorial Sloan-Kettering Cancer Center, New York, New York, USA, email: schumanm@mskcc.org
Abstract:
Many of the chemotherapy/biotherapy agents that are used in the treatment of cancer have the potential to cause hypersensitivity reactions. Intravenous Leucovorin Calcium (LV), or folinic acid, has been used in the treatment of gastrointestinal cancers for more than 50 years. Hypersensitivity/anaphylactoid reaction is listed as a rare, but possible side effect by the manufacturer and multiple drug references, and may occur with either oral or parenteral administration. A thorough review of the literature revealed only one documented description of an anaphylactoid reaction to LV. LV is used in combination with agents known to cause hypersensitivity reactions. The purpose of this presentation is to educate oncology nurses to consider seemingly benign drugs, such as LV, as the causative agent of a hypersensitivity reaction. A case study will be presented to illustrate this point. A multidisciplinary group with representatives from nursing, pharmacy, and physicians was formed that undertook a retrospective review of Adverse Drug Reporting (ADR) forms as well as the corresponding patient charts of patients receiving 5-FU/LV containing regimens from January 1 to December 31, 2004. From this review, a cluster of symptoms characteristic of a reaction to LV were determined. A total of six patients felt to have had a reaction to LV were identified. As a result of our findings, oncology nurses have been educated to recognize LV as an agent capable of causing hypersensitivity, and physicians are now considering discontinuing the LV in patients who have exhibited this symptom cluster rather than routinely changing the treatment regime.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleCASE STUDY: LEUCOVORIN HYPERSENSITIVITY, MORE COMMON THAN YOU MIGHT THINK.en_GB
dc.contributor.authorSchumann, Maryen_US
dc.author.detailsMary Schumann, RN MA AOCN, Clinical Nurse Specialist, Memorial Sloan-Kettering Cancer Center, New York, New York, USA, email: schumanm@mskcc.orgen_US
dc.identifier.urihttp://hdl.handle.net/10755/165121-
dc.description.abstractMany of the chemotherapy/biotherapy agents that are used in the treatment of cancer have the potential to cause hypersensitivity reactions. Intravenous Leucovorin Calcium (LV), or folinic acid, has been used in the treatment of gastrointestinal cancers for more than 50 years. Hypersensitivity/anaphylactoid reaction is listed as a rare, but possible side effect by the manufacturer and multiple drug references, and may occur with either oral or parenteral administration. A thorough review of the literature revealed only one documented description of an anaphylactoid reaction to LV. LV is used in combination with agents known to cause hypersensitivity reactions. The purpose of this presentation is to educate oncology nurses to consider seemingly benign drugs, such as LV, as the causative agent of a hypersensitivity reaction. A case study will be presented to illustrate this point. A multidisciplinary group with representatives from nursing, pharmacy, and physicians was formed that undertook a retrospective review of Adverse Drug Reporting (ADR) forms as well as the corresponding patient charts of patients receiving 5-FU/LV containing regimens from January 1 to December 31, 2004. From this review, a cluster of symptoms characteristic of a reaction to LV were determined. A total of six patients felt to have had a reaction to LV were identified. As a result of our findings, oncology nurses have been educated to recognize LV as an agent capable of causing hypersensitivity, and physicians are now considering discontinuing the LV in patients who have exhibited this symptom cluster rather than routinely changing the treatment regime.en_GB
dc.date.available2011-10-27T12:12:53Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:12:53Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.